Index DJIA, S&P 500
P/E 21.64
EPS (ttm) 4.77
Insider Own 0.10%
Shs Outstand 2.53B
Perf Week 1.44%
Market Cap 265.93B
Forward P/E 10.99
EPS next Y 9.41
Insider Trans 0.00%
Shs Float 2.53B
Perf Month -5.82%
Income 12.15B
PEG 0.91
EPS next Q 1.85
Inst Own 79.07%
Short Float 1.03%
Perf Quarter -9.66%
Sales 62.89B
P/S 4.23
EPS this Y 412.98%
Inst Trans 1.12%
Short Ratio 2.84
Perf Half Y -20.07%
Book/sh 17.58
P/B 5.88
EPS next Y 21.45%
ROA 10.83%
Short Interest 26.04M
Perf Year 0.94%
Cash/sh 5.69
P/C 18.17
EPS next 5Y 23.85%
ROE 28.33%
52W Range 98.60 - 134.63
Perf YTD -5.21%
Dividend Est. 3.05 (2.95%)
P/FCF 17.92
EPS past 5Y -42.70%
ROI 15.28%
52W High -23.24%
Beta 0.41
Dividend TTM 3.08 (2.98%)
Quick Ratio 1.15
Sales past 5Y 7.72%
Gross Margin 73.03%
52W Low 4.81%
ATR (14) 1.89
Dividend Ex-Date Sep 16, 2024
Current Ratio 1.36
EPS Y/Y TTM 163.70%
Oper. Margin 23.00%
RSI (14) 38.80
Volatility 1.69% 1.74%
Employees 72000
Debt/Eq 0.86
Sales Y/Y TTM 8.17%
Profit Margin 19.32%
Recom 1.58
Target Price 131.16
Option/Short Yes / Yes
LT Debt/Eq 0.79
EPS Q/Q -33.34%
Payout 2065.60%
Rel Volume 0.41
Prev Close 102.92
Sales Surprise 1.11%
EPS Surprise 5.80%
Sales Q/Q 4.42%
Earnings Oct 31 BMO
Avg Volume 9.18M
Price 103.34
SMA20 -1.50%
SMA50 -6.42%
SMA200 -14.99%
Trades
Volume 208,879
Change 0.41%
Date
Action
Analyst
Rating Change
Price Target Change
Today Downgrade
Daiwa Securities
Buy → Neutral
Oct-17-24 Initiated
Bernstein
Mkt Perform
$115
Mar-11-24 Downgrade
Societe Generale
Hold → Sell
$104
Jan-04-24 Upgrade
TD Cowen
Market Perform → Outperform
$125 → $135
Nov-09-23 Initiated
Deutsche Bank
Buy
$115
Oct-27-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$132
Oct-20-23 Upgrade
UBS
Neutral → Buy
$117 → $122
Jul-14-23 Initiated
HSBC Securities
Hold
$123
Apr-13-23 Upgrade
Citigroup
Neutral → Buy
$105 → $130
Mar-28-23 Downgrade
Societe Generale
Buy → Hold
Mar-13-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$120 → $115
Mar-06-23 Initiated
Jefferies
Buy
$125
Feb-22-23 Upgrade
Wolfe Research
Peer Perform → Outperform
$127
Jan-04-23 Upgrade
BofA Securities
Neutral → Buy
$110 → $130
Nov-18-22 Initiated
Credit Suisse
Outperform
$120
Oct-10-22 Upgrade
Guggenheim
Neutral → Buy
Sep-14-22 Upgrade
Berenberg
Hold → Buy
$95 → $100
Jul-06-22 Upgrade
Daiwa Securities
Neutral → Buy
$89 → $102
Jun-06-22 Resumed
SVB Leerink
Outperform
$102
Apr-06-22 Resumed
Morgan Stanley
Equal-Weight
$80
Show Previous Ratings
Nov-09-24 10:41AM
Nov-08-24 02:47PM
11:23AM
09:36AM
09:00AM
10:36AM
Loading…
Nov-07-24 10:36AM
07:00AM
Nov-06-24 06:45AM
Nov-04-24 06:41PM
Nov-01-24 02:33PM
03:08AM
01:55AM
(Thomson Reuters StreetEvents)
Oct-31-24 04:12PM
(Investor's Business Daily)
02:03PM
01:15PM
10:03AM
Loading…
10:03AM
07:09AM
06:37AM
(Associated Press Finance)
06:35AM
06:30AM
(Investor's Business Daily)
06:30AM
Oct-30-24 12:44PM
01:29AM
Oct-28-24 12:45PM
06:45AM
Oct-27-24 08:58AM
01:39AM
Oct-25-24 06:47PM
04:15PM
Oct-24-24 02:46PM
01:42PM
Loading…
01:42PM
(Pharmaceutical Technology)
01:25PM
10:01AM
09:00AM
06:45AM
Oct-23-24 07:58PM
03:35PM
10:06AM
07:45AM
Oct-22-24 05:50PM
Oct-21-24 12:28PM
Oct-20-24 03:00PM
Oct-19-24 05:09PM
11:57AM
Oct-18-24 04:46PM
(Pharmaceutical Technology)
03:25PM
08:08AM
03:20AM
Oct-17-24 06:34PM
06:00PM
01:41PM
Oct-16-24 04:21PM
(Investor's Business Daily)
06:45AM
02:00AM
Oct-15-24 06:09PM
(Investor's Business Daily)
05:50PM
Oct-14-24 08:27AM
08:00AM
Oct-12-24 12:37PM
Oct-11-24 09:00AM
08:38AM
Oct-10-24 10:57AM
Oct-09-24 11:21AM
(Pharmaceutical Technology)
06:45AM
05:30AM
Oct-08-24 03:44PM
06:45AM
Oct-07-24 06:33AM
Oct-06-24 03:36PM
Oct-04-24 09:40AM
Oct-03-24 08:30AM
(Investor's Business Daily)
08:30AM
Oct-01-24 06:45AM
06:30AM
Sep-30-24 12:30PM
04:50AM
Sep-29-24 06:28AM
Sep-27-24 12:09PM
06:38AM
Sep-26-24 12:23PM
06:45AM
04:27AM
Sep-25-24 03:54PM
08:32AM
06:45AM
06:30AM
12:11AM
Sep-24-24 08:06AM
Sep-20-24 10:48AM
09:00AM
07:30AM
Sep-19-24 09:00AM
Sep-18-24 02:45PM
06:45AM
04:52AM
Sep-17-24 07:58AM
07:51AM
06:00AM
Sep-16-24 07:00AM
Sep-15-24 10:30AM
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Guindo Chirfi Chief Marketing Officer Aug 05 '24 Option Exercise 115.20 36,901 4,250,995 57,782 Aug 06 12:20 PM Smart Dalton SVP Fin. - Global Controller May 03 '24 Option Exercise 128.26 2,046 262,420 4,708 May 06 04:10 PM Smart Dalton SVP Fin. - Global Controller May 04 '24 Option Exercise 127.51 612 78,036 4,730 May 06 04:10 PM DeLuca Richard R. EVP&Pres, Merck Animal Heallth May 04 '24 Option Exercise 127.51 27,126 3,458,836 163,720 May 06 04:08 PM Klobuchar Michael A EVP - Chief Strategy Officer May 04 '24 Option Exercise 127.51 887 113,101 24,058 May 06 04:06 PM Oosthuizen Johannes Jacobus President, U.S. Market May 04 '24 Option Exercise 127.51 912 116,289 24,271 May 06 04:01 PM Romanelli Joseph President, Human Health Int?l May 02 '24 Option Exercise 128.80 2,262 291,346 21,831 May 02 04:29 PM Smart Dalton SVP Fin. - Global Controller May 02 '24 Option Exercise 128.80 381 49,073 3,048 May 02 04:23 PM Merck & Co., Inc. 10% Owner Mar 11 '24 Buy 23.00 21,397,205 492,135,715 1,000 Mar 11 03:27 PM Litchfield Caroline EVP & CFO Feb 14 '24 Option Exercise 58.08 38,291 2,223,941 89,199 Feb 15 04:03 PM Litchfield Caroline EVP & CFO Feb 14 '24 Sale 125.50 38,291 4,805,520 50,908 Feb 15 04:03 PM Davis Robert M Chairman, CEO & President Feb 13 '24 Option Exercise 74.18 150,000 11,127,160 498,327 Feb 15 04:01 PM Davis Robert M Chairman, CEO & President Feb 14 '24 Option Exercise 73.73 85,021 6,268,598 433,348 Feb 15 04:01 PM Davis Robert M Chairman, CEO & President Feb 13 '24 Sale 125.85 150,000 18,877,424 348,327 Feb 15 04:01 PM Davis Robert M Chairman, CEO & President Feb 14 '24 Sale 125.40 85,021 10,661,574 348,327 Feb 15 04:01 PM Romanelli Joseph President, Human Health Int?l Feb 13 '24 Sale 124.89 1,000 124,888 19,569 Feb 14 04:03 PM Li Dean Y Executive VP & President, MRL Feb 09 '24 Option Exercise 62.07 14,702 912,553 60,944 Feb 12 04:03 PM Li Dean Y Executive VP & President, MRL Feb 09 '24 Sale 125.50 14,702 1,845,083 46,242 Feb 12 04:03 PM Williams David Michael EVP,Chief Info&Digital Officer Feb 07 '24 Sale 127.57 1,451 185,108 19,812 Feb 08 04:04 PM Oosthuizen Johannes Jacobus President, U.S. Market Feb 02 '24 Option Exercise 78.80 20,937 1,649,906 42,286 Feb 05 04:01 PM Oosthuizen Johannes Jacobus President, U.S. Market Feb 02 '24 Sale 127.17 18,959 2,411,111 23,327 Feb 05 04:01 PM MIZELL STEVEN EVP, Chief HR Officer Feb 02 '24 Option Exercise 73.65 32,994 2,430,159 74,313 Feb 02 04:07 PM MIZELL STEVEN EVP, Chief HR Officer Feb 02 '24 Sale 126.65 50,694 6,420,349 23,619 Feb 02 04:07 PM Zachary Jennifer EVP, General Counsel Feb 02 '24 Option Exercise 87.10 19,417 1,691,221 78,557 Feb 02 04:05 PM Zachary Jennifer EVP, General Counsel Feb 02 '24 Sale 126.97 49,499 6,284,779 29,058 Feb 02 04:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite